Last reviewed · How we verify
glutamate infusion
glutamate infusion is a Small molecule drug developed by University Hospital, Linkoeping. It is currently in Phase 3 development for Treatment-resistant depression, Alzheimer's disease. Also known as: glutamate.
Glutamate infusion works by increasing the concentration of glutamate in the brain, which can help to stimulate neural activity and improve cognitive function.
Glutamate infusion works by increasing the concentration of glutamate in the brain, which can help to stimulate neural activity and improve cognitive function. Used for Treatment-resistant depression, Alzheimer's disease.
-
Baseline phase 3 → approval rate
+58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas). -
CNS / neurology attrition
-3.0pp
CNS drugs have historically high Phase 3 failure rates (notably in Alzheimer disease + major depression).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2028–2030 | — |
| EMA | EU | 2029–2031 | +0.7 yr |
| MHRA | GB | 2029–2031 | +0.7 yr |
| Health Canada | CA | 2029–2032 | +0.9 yr |
| TGA | AU | 2029–2032 | +1.2 yr |
| PMDA | JP | 2029–2032 | +1.5 yr |
| NMPA | CN | 2030–2033 | +2.3 yr |
| MFDS | KR | 2029–2032 | +1.4 yr |
| CDSCO | IN | 2029–2033 | +1.8 yr |
| ANVISA | BR | 2030–2033 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | glutamate infusion |
|---|---|
| Also known as | glutamate |
| Sponsor | University Hospital, Linkoeping |
| Target | NMDA receptor |
| Modality | Small molecule |
| Therapeutic area | Neurology |
| Phase | Phase 3 |
Mechanism of action
Glutamate is the primary excitatory neurotransmitter in the brain, and increasing its concentration can help to enhance neural communication and plasticity. This can be particularly beneficial for individuals with conditions such as Alzheimer's disease or stroke, where cognitive decline is a major concern.
Approved indications
- Treatment-resistant depression
- Alzheimer's disease
Common side effects
- Headache
- Nausea
- Fatigue
Key clinical trials
- A Study to Compare Sacituzumab Tirumotecan (MK-2870) Monotherapy Versus Treatment of Physician's Choice as Second-line Treatment for Participants With Recurrent or Metastatic Cervical Cancer (MK-2870-020/TroFuse-020/Gog-3101/ENGOT-cx20) (PHASE3)
- Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009) (PHASE3)
- A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019) (PHASE3)
- Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in 1L Non-Small Cell Lung Cancer (TROPION-Lung07) (PHASE3)
- A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009) (PHASE3)
- Phase III Study of AK112 for NSCLC Patients (PHASE3)
- BBO-11818 in Adult Subjects With KRAS Mutant Cancer (PHASE1)
- A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- glutamate infusion CI brief — competitive landscape report
- glutamate infusion updates RSS · CI watch RSS
- University Hospital, Linkoeping portfolio CI
Frequently asked questions about glutamate infusion
What is glutamate infusion?
How does glutamate infusion work?
What is glutamate infusion used for?
Who makes glutamate infusion?
Is glutamate infusion also known as anything else?
What development phase is glutamate infusion in?
What are the side effects of glutamate infusion?
What does glutamate infusion target?
Related
- Target: All drugs targeting NMDA receptor
- Manufacturer: University Hospital, Linkoeping — full pipeline
- Therapeutic area: All drugs in Neurology
- Indication: Drugs for Treatment-resistant depression
- Indication: Drugs for Alzheimer's disease
- Also known as: glutamate
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing